Product Description
Mechanisms of Action: NGF Binder
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Osteoarthritis|Osteoarthritis, Knee|Osteoarthritis, Hip
Phase 2: Mononeuropathies|Neuralgia, Postherpetic|Low Back Pain|Peripheral Nervous System Diseases|Cancer Pain|Arthralgia|Osteoarthritis, Hip|Osteoarthritis, Knee|Chronic Pain|Cystitis, Interstitial|Urinary Bladder Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2014-003224-40 | P3 |
Terminated |
Osteoarthritis, Knee|Osteoarthritis, Hip |
2017-02-11 |
|
CR100070 | P3 |
Completed |
Osteoarthritis |
2016-10-10 |
|
CR106249 | P3 |
Completed |
Osteoarthritis |
2016-09-19 |
|
2013-001830-16 | P3 |
Completed |
Osteoarthritis, Hip|Osteoarthritis, Knee |
2016-09-19 |